Targeting inflammasome/IL-1 pathways for cancer immunotherapy.
about
Inflammasomes in Inflammation-Induced Cancer.Identification and validation of uterine stimulant methylergometrine as a potential inhibitor of caspase-1 activationInflammasomes and Cancer: The Dynamic Role of the Inflammasome in Tumor DevelopmentIn Search of a Converging Cellular Mechanism in Nanotoxicology and Nanomedicine in the Treatment of Cancer.Casticin inhibits interleukin-1β-induced ICAM-1 and MUC5AC expression by blocking NF-κB, PI3K-Akt, and MAPK signaling in human lung epithelial cells.Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth.Blockage of the NLRP3 inflammasome by MCC950 improves anti-tumor immune responses in head and neck squamous cell carcinoma.Integrating the dysregulated inflammasome-based molecular functionome in the malignant transformation of endometriosis-associated ovarian carcinoma.Interleukin-1 receptor antagonist inhibits angiogenesis via blockage IL-1α/PI3K/NF-κβ pathway in human colon cancer cell.Immunogenetics of prostate cancer: a still unexplored field of study.The contrasting roles of inflammasomes in cancer.The role of IL-1B in breast cancer bone metastasis.Plasmatic membrane toll-like receptor expressions in human astrocytomas.BRAF inhibitors stimulate inflammasome activation and interleukin 1 beta production in dendritic cells.Inhibition of interleukin-1 receptor-associated kinase 1 (IRAK1) as a therapeutic strategyCancer Cells Exploit Notch Signaling to Redefine a Supportive Cytokine MilieuNitric oxide deficiency and endothelial-mesenchymal transition of pulmonary endothelium in the progression of 4T1 metastatic breast cancer in mice
P2860
Q37699536-1D9AF6C8-9ACD-4D1D-B9A0-257EB810CFABQ38654164-71BDBF3F-4737-4246-BF65-CDDB72118BE6Q41684112-1C5ED0C4-2AA3-49BC-AB89-EC93902B29C8Q46828103-07CDCA77-0205-4574-B0B4-3AC756ED4F6EQ47155326-F642F8D5-4B45-4A13-82DD-7452C651B816Q47390109-07A28688-C99D-42BF-A33C-9050B9A17BA2Q48220238-49C21B3D-E2D9-458A-9015-A86FEC7674CEQ49619868-3B71C6D3-11C4-4E90-B63C-CA4714A93067Q50073141-3862ABD4-B277-45B7-BCD0-768C610F4B30Q50082109-D5F0E349-BCDD-4CE2-B503-B4253DF87F0FQ54486845-0E742D57-F64A-466B-85CE-C7B3DBFDFF54Q55239567-5C3A7E6C-2769-49DF-B387-F81E660EF54AQ55279509-DCCEDBF0-5407-401D-990A-F8C86927938FQ55467257-2465B76A-0519-4A74-8FAC-F9ABEF212B6AQ57116991-04CD4242-2597-4CE6-8738-E00ACE13FD50Q58781616-2BB1AA1B-6D23-4A60-B43F-5BA41015D837Q58801313-83159259-EAAC-4B93-B0FB-197396EBEDE5
P2860
Targeting inflammasome/IL-1 pathways for cancer immunotherapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 October 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting inflammasome/IL-1 pathways for cancer immunotherapy.
@en
Targeting inflammasome/IL-1 pathways for cancer immunotherapy.
@nl
type
label
Targeting inflammasome/IL-1 pathways for cancer immunotherapy.
@en
Targeting inflammasome/IL-1 pathways for cancer immunotherapy.
@nl
prefLabel
Targeting inflammasome/IL-1 pathways for cancer immunotherapy.
@en
Targeting inflammasome/IL-1 pathways for cancer immunotherapy.
@nl
P2093
P2860
P356
P1433
P1476
Targeting inflammasome/IL-1 pathways for cancer immunotherapy.
@en
P2093
P2860
P2888
P356
10.1038/SREP36107
P407
P577
2016-10-27T00:00:00Z